头孢哌酮钠舒巴坦钠治疗重症下呼吸道医院感染的临床疗效  

The Clinical Efficacy of Cefoperazone Sodium and Sulbactam Sodium in Treatment of Severe Lower Respiratory Tract Nosocomial Infection

作　　者：徐真[1] 朱金玉[1] 

机构地区：[1]河南省南阳市中心医院医院感染管理科,河南南阳473000

出　　处：《中国卫生标准管理》2016年第16期121-122,共2页China Health Standard Management

摘　　要：目的 探讨头孢哌酮钠舒巴坦钠治疗重症下呼吸道医院感染的临床效果。方法 根据治疗药物的不同将2014年1月-2015年1月在我院住院的102例重症下呼吸道医院感染患者分为头孢他啶组和头孢哌酮钠舒巴坦钠组,并比较两组患者临床治疗效果和不良反应发生率。结果头孢哌酮钠舒巴坦钠组患者临床治疗总有效率和不良反应发生率与头孢他啶组比较差异无统计学意义（P〉0.05）。结论 与头孢他啶比较,头孢哌酮钠舒巴坦钠在治疗重症下呼吸道医院感染方面临床效果相近,且不良反应较轻微。Objective To discuss the clinical effect of cefoperazone sodium and sulbactam sodium in treatment of severe lower respiratory tract nosocomial infection. Methods 102 cases of severe lower respiratory tract infection from the January 2014 to January 2015 in our hospital were divided into groups of ceftazidime and cefoperazone sulbactam group according to treatment, and the clinical and patient outcomes incidence of adverse reactions of two groups were compared. Results Difference of efficient and incidence of adverse reactions with ceftazidime group was not statistically significant （P〉0.05 ） . Conclusion Compared with ceftazidime, cefoperazone sulbactam respiratory hospital infections shows similar clinical effects, and adverse reactions are mild.

关 键 词：医院感染 重症下呼吸道感染 头孢哌酮钠舒巴坦钠 头孢他啶 临床效果 

分 类 号：R23[医药卫生—中医学]